Kadın ve Epilepsi

Öz

Epilepsi tüm yaş gruplarında görülebildiğinden, doğurganlık çağındaki kadınları da etkileyebilir. Epilepsili bir kadının tedavisi, epilepsili bir erkeğin tedavisinden farklıdır. Çünkü epilepsi ve tedavide kullanılan antiepileptik ilaçlar (AEİ)  cinsel gelişimi, menstrual siklusu, kontrasepsiyonu, fertiliteyi, gebeliği, emzirmeyi ve menapozu etkileyebilir. Bu makalede kadın hastada epilepsi yönetimi tartışılacaktır.

Anahtar Kelimeler

• Epilepsi,Gebelik,Kadın,Kontrasepsiyon,Tedavi

Epilepsy and Women

Öz

Since epilepsy can be seen in all age groups, it can also affect women of childbearing age. The treatment of epilepsy in women is very different from the treatment of men with epilepsy. Because epilepsy and antiepileptic drugs (AEDs) used in the treatment can affect sexual development, menstrual cycle, contraception, fertility, pregnancy, lactation and menopause. This article discusses the management of epilepsy in a female patient.

Anahtar Kelimeler

• Contraception,Epilepsy,Pregnancy,Treatment,Women

Kaynakça

1. 1. Geda G, Caksen H, Içağasioğlu D. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy. Acta Neurol Belg. 2002;102(3):122-6.
2. 2. Luef G, Rauchenzauner M. Epilepsy and hormones: a critical review. Epilepsy Behav. 2009;15(1):73-7.
3. 3. Isojärvi JI, Taubøll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs. 2005;19(3):207-23.
4. 4. Lobo RA. A disorder without identity: "HCA," "PCO," "PCOD," "PCOS," "SLS". what are we to call it?! Fertil Steril. 1995; 63(6):1158-60.
5. 5. Isojärvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllylä VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39(5):579-84.
6. 6. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV. Polycysticovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl JMed. 1993; 329(19):1383-8.
7. 7. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia. 1995;36(7):676-81.
8. 8. Garnotel R, Monier F, Lefèvre F, Gillery P. Long-term variability of serum lipoprotein(a) concentrations in healthy fertile women. Clin Chem Lab Med. 1998; 36 (5): 317-21

9. 9. Drislane FW, Coleman AE, Schomer DL, Ives J, Levesque LA, Seibel MM, Herzog AG. Altered pulsatile secretion of luteinizing hormone in women with epilepsy.Neurology. 1994;44(2):306-10.
10. 10. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997; 38(10):1082-8.
11. 11. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol. 2004;56(3):431-4.
12. 12. Herzog AG. Catamenial Epilepsi: Update prevelance, pathophysiology and treatment from findings of NIH progesteron treatment trial. Seizure 2015;28:18-25.
13. 13. Crawford P, Appleton R, Betts T, Duncan J, Guthrie E, Morrow J. Best practice guidelines for the management of women with epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure. 1999;8(4): 201-17.
14. 14. Betts T, Crawford P. Women and Epilepsy. London, UK: Martin Dunitz; 1998. pp. 27–28.
15. 15. Herzog AG, Drislane FW, Schomer DL, Levesque LA, Ives J, Blume HW, Dubuisson D, Cosgrove GR. Abnormal pulsatile secretion of luteinizing hormone in men with epilepsy: relationship to laterality and nature of paroxysmal discharges. Neurology. 1990;40(10):1557-61.
16. 16. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia. 2005;46(S9):117-24.
17. 17. Smith PE. UK Oxcarbazepine Advisory Board. Clinical recommendations for oxcarbazepine. Seizure. 200;10(2):87-91.
18. 18. Tettenborn B, Genton P, Polson D. Epilepsy and women's issues: an update. Epileptic Disord. 2002;4(Suppl 2):23-31.
19. 19. Crawford PM. Managing epilepsy in women of childbearing age. Drug Saf. 2009;32(4):293-307.
20. 20. Kutlu G. Kadın ve Epilepsi. In: Yeni N, Gürses C. Epilepsi Çalışma grubu Tanı ve Tedavi Rehberi. 2015; 45-51, Türk Nöroloji Derneği Yayınları.
21. 21. Wyszynski DF, Nambisan M, Surve T et al. Antiepileptic drug pregnancy registry: Increased rate of major malformations in offspring exposed to valporate during pregnancy. Neurology. 2003;64:961-65.
22. 22. Vajda FJ, O'brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci. 2004;11(8): 854-8.
23. 23. Mawer G, Clayton-Smith J, Coyle H, Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure. 2002;11(8): 512-8.
24. 24. Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology. 2001;57(2): 321-4.
25. 25. Cunnington M, Tennis P. International Lamotrigine Pregnancy RegistryScientific Advisory Committee. Lamotrigine and the risk of malformations inpregnancy. Neurology. 2005;64(6): 955-60.
26. 26. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77(2):193-8.
27. 27. Hernández-Díaz S, Smith CR, Shen A, et al. North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692-9.
28. 28. Tomson T, Xue H, Battino D. Major congenital malformations in children of women with epilepsy. Seizure. 2015;28: 40-4.
29. 29. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360(16):1597-605.
30. 30. Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696-703.
31. 31. Tomson T, Danielsson BR, Winbladh B. Epilepsy and pregnancy. Balancing between risks to the mother and child. Lakartidningen. 1997;94(34):2827-32.
32. 32. Schmidt D, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry. 1983;46 (8):751-5.
33. 33. Sveberg L, Svalheim S, Taubøll E. The impact of seizures on pregnancy and delivery. Seizure. 2015;28:29-32.
34. 34. Crawford P. Epilepsy and pregnancy. Seizure. 2002;11 (Suppl A):212-9.
35. 35. Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):142-9.
36. 36. Borthen I, Eide MG, Daltveit AK, Gilhus NE. Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. BJOG. 2011;118(8):956-65.
37. 37. Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav. 2004;5(1):102-5.
38. 38. Veiby G, Bjørk M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breast feeding. Seizure. 2015;28:57-65.
39. 39. Harden CL. Menopause and bone density issues for women with epilepsy. Neurology. 2003;61(6 Suppl 2):16-22.
40. 40. Abbasi F, Krumholz A, Kittner SJ, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia. 1999;40(2):205-10.